Webinar | Integration of Artificial Intelligence with Digital Pathology: Deployment Considerations & Cases Studies in Pharma
WEBINAR ANNOUNCEMENT
Integration of Artificial Intelligence with Digital Pathology:
Deployment Considerations & Cases Studies in Pharma
24 April, 2019
7:00 PDT | 10:00 EDT | 15:00 BST | 22:00 CST
PRESENTED BY
Daniel Sutton | Senior Scientist Pathology Sciences, AstraZeneca, R&D Innovative Medicines, Drug Safety & Metabolism
Hosted by Dr. Kate Lillard Tunstall | Chief Scientific Officer, Indica Labs, Incrations and Cases Studies in Drug Discovery and Pre-Clinical Safety Assessment
By helping scientists make data-driven decisions faster and more efficiently, artificial intelligence (AI) is revolutionizing drug discovery and development. Pathology is no exception and the Pathology Sciences team at AstraZeneca in Cambridge UK is leading the charge. Here, neural networks are being deployed to search digital slides for specific tissue classes, features and pathologies that are not easily quantified using traditional image analysis or are too time-consuming for pathologists to quantify by eye.
While AI holds great promise in pathology, it is key to understand the advantages and limitations of the technology in equal measure, the technical (hardware and software) requirements for different deployments, and financial practicalities. In this one-hour webinar, Daniel Sutton, Senior Scientist at AstraZeneca, will discuss the deployment of AI within the Pathology Science group including:
- Expertise and technology within the group as it relates to image analysis and AI
- Different deployment models for AI and the vendor selection process
- Selection of projects – when does it make sense to use AI?
- The validation processes
- Four practical use-cases for AI in drug discovery and safety assessment
Prior to the main presentation, Dr. Kate Lillard Tunstall will give a brief introduction to Indica Labs’ HALO AI solution, introduce some additional use-cases for AI in pathology, and explain how you can get started with AI today.
Who should attend? This webinar is highly recommended for pathologists and scientists with interest in –
- Artificial intelligence, deep learning, machine learning, convolutional neural networks for pathology tissue classification
- Image analysis for digital pathology
- Drug discovery research using tissues (especially oncology)
- Pre-clinical safety assessment/tox pathology
- Time-savings in pathology evaluations for drug development
Register Here
Daniel Sutton
Senior Scientist Pathology Sciences
AstraZeneca
R&D Innovative Medicines, Drug Safety & Metabolism
Daniel is a senior scientist in the Pathology Sciences group which is contained within the Drug Safety and Metabolism department at AstraZeneca UK. The group is focused on small scale toxicology studies and interacts with early stage research when pathology support is required. Daniel joined AstraZeneca in 2015. He started his career in the NHS as a biomedical scientist in pathology before moving into the pharmaceutical industry as a research scientist at UCB and later at Novartis. Since then, he has worked within a range of companies from start-ups to multinationals in positions focused on pathology. During his career, Daniel has had the opportunity to work with a wide range of image analysis and artificial intelligence platforms for digital pathology, including solutions from Definiens, Aperio, Visiopharm and Indica Labs.
Dr. Kate Lillard Tunstall
Chief Scientific Officer
Indica Labs, Inc
Kate received her PhD in Molecular Genetics and Biochemistry from the University of Cincinnati Medical Center, followed by a Howard Hughes postdoctoral fellowship at the University of Texas Southwestern Medical Center. While conducting research in the area of stem cell biology and oncology as a graduate and postdoctoral fellow, Kate developed a keen interest in IHC and image analysis. Following this, she joined Aperio in 2007 where she supported and then managed image analysis products for digital pathology. After acquisition of Aperio by Leica in late 2012, Kate joined Indica Labs as CSO where she supports, promotes, and helps guide the development of digital pathology image analysis and artificial intelligence solutions for the life sciences.
ABOUT INDICA LABS, INC
Indica Labs’ image analysis and collaborative image management software platforms, HALO, HALO-AI and HALO -Link, facilitate quantitative evaluation of digital pathology images. With unmatched ease-of-use, speed and scalability, pharmaceutical, healthcare and research organizations worldwide are using Indica Labs’ software and services for high-throughput, quantitative tissue analysis in oncology, neuroscience, metabolism, and toxicology.
CONTACT US
info@indicalab.com
USA +1 505 492-0979 | UK/EU +44 1789 765 721
http://indicalab.com
Source: IndicaLabs
